Cancer Drug Predictive Analysis

Genomic Data & Drug Sensitivity Input

Cancer Type:

📊 Genomic Markers

TMB (Tumor Mutational Burden) per Mb:

MSI Status:

PD-L1 Expression (%):

MMR Status:

TP53 Mutation Status:

BRCA1/BRCA2 Status:

Driver Mutations (comma-separated):

💊 Drug Sensitivity Data

IC50 Value (μM):

AUC Score:

Drug Name:

Drug Class:

CYP3A4 Metabolism:

Resistance Score (0-100):

Prior Clinical Response:

About Genomic-Drug Sensitivity Prediction

This tool predicts cancer drug response based on genomic markers and drug sensitivity data. It analyzes tumor mutational characteristics and drug-specific parameters to estimate treatment efficacy.

🧬 Genomic Markers Analyzed:

Tumor Mutational Burden (TMB) - Indicates immune response potential
Microsatellite Instability (MSI) - Associated with checkpoint inhibitor response
PD-L1 Expression - Predictive for immunotherapy response
Mismatch Repair (MMR) Status - Impacts treatment selection
Driver Mutations - Gene-specific treatment targeting
TP53 & BRCA Status - Associated with treatment sensitivity

💊 Drug Sensitivity Parameters:

IC50 - Concentration required for 50% growth inhibition
AUC - Area Under Curve; measure of drug efficacy
Resistance Score - Likelihood of acquired resistance
Drug Metabolism - CYP3A4 status affects bioavailability

⚠️ Disclaimer: Results are for research and educational purposes. Clinical decisions should be made in consultation with oncologists using comprehensive patient data and clinical trial evidence.

🧬 Cancer Drug Response Predictor

Genomic Data & Drug Sensitivity Input

Prediction Results

Drug Response Prediction Score

Predicted Response Category

Genomic-Drug Compatibility

Sensitivity Assessment

Clinical Recommendation

About Genomic-Drug Sensitivity Prediction